Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668564 · ClinicalTrials.gov registry record · Phase 2
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00668564 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 18 participants.
The verdict
NCT00668564, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- PROCEDURE Stem Cell Transplantation
- DRUG Campath-1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668564
The ClinicalTrials.gov registry entry for NCT00668564 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00668564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668564 about?
NCT00668564 is a clinical study titled "Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism". The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).
What is the current status of trial NCT00668564?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00668564?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Stem Cell Transplantation (PROCEDURE), Campath-1H (DRUG).
Who is sponsoring clinical trial NCT00668564?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.